• Explore /
  • Poster
  • / A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

Abstract Video & Slides Poster

Authors

null

Laurie Helen Sehn

BC Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, BC, Canada

Laurie Helen Sehn , Christian W Scholz , Stefano Luminari , Antonio Salar , Bjorn E. Wahlin , Ajay K. Gopal , Christophe Marc Bonnet , Shankara Paneesha , Oliver Manzke , Francis Seguy , Di Li , Kai Hübel

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT04680052

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS7568)

DOI

10.1200/JCO.2021.39.15_suppl.TPS7568

Abstract #

TPS7568

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Laurie Helen Sehn

First Author: John Leonard

First Author: Umberto Vitolo

First Author: Loretta J. Nastoupil